Spectrum Pharma Introduces Marqibo & Ships First Commercial Orders

(RTTNews) - Spectrum Pharmaceuticals (SPPI) announced the launch of Marqibo. In addition, the company confirmed the shipment of its first commercial orders for Marqibo.

Rajesh Shrotriya, Spectrum Pharmaceuticals' chairman & chief executive said, "Within two months after the Talon acquisition, we are making Marqibo, our fourth commercial product, available to patients in the US."

Marqibo, a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine, can be accessed through Spectrum Therapy Access Resources which is a reimbursement support, co-pay assistance, and patient assistance program designed to help patients and healthcare professionals gain appropriate access to drugs.